Agertoft L, Pedersen S
Department of Paediatrics, Kolding Hospital, Denmark.
Arch Dis Child. 1994 Sep;71(3):217-9; discussion 219-20. doi: 10.1136/adc.71.3.217.
The budesonide dose delivered to the patient from three different spacer devices (Nebuhaler = 750 ml, Aerochamber = 140 ml, and Babyspacer = 260 ml) was assessed by measuring the budesonide dose deposited on a filter inserted between the spacer outlet and the mouth of the patient. Twenty children aged 10-25 months were given a single dose of 200 micrograms budesonide from each spacer device in a randomised crossover study. All spacers had a facemask attached and a one way valve system. The children breathed through the inhalation system for 30 seconds. Furthermore, the minute ventilation of the children through a tightly fitting facemask was measured. The filter dose of budesonide was significantly lower after Aerochamber treatment (39.4 micrograms, range 19-67 micrograms) than after Nebuhaler (53.5 micrograms, range 34-88 micrograms) and Babyspacer (55.5 micrograms, range 39-76 micrograms) treatment. The minute ventilation of the children varied from 1.4 l/min to 7.0 l/min (mean 5.0 l/min). This was sufficient to empty all spacers within the 30 seconds of inhalation. It is concluded that spacer volume does not seem to be so important for children aged 10-25 months as long as spacers with a volume lower than 750 ml are used.
通过测量沉积在置于储雾罐出口与患者口腔之间滤器上的布地奈德剂量,评估了三种不同储雾罐装置(百瑞雾化吸嘴=Nebuhaler,容积750毫升;爱全乐储雾罐=Aerochamber,容积140毫升;小儿储雾罐=Babyspacer,容积260毫升)输送给患者的布地奈德剂量。在一项随机交叉研究中,给20名年龄在10至25个月的儿童从每个储雾罐装置中各给予单剂量200微克布地奈德。所有储雾罐均配有面罩和单向阀系统。儿童通过吸入系统呼吸30秒。此外,还测量了儿童通过紧密贴合面罩时的分钟通气量。使用爱全乐储雾罐治疗后,布地奈德的滤器剂量(39.4微克,范围19至67微克)显著低于使用百瑞雾化吸嘴(53.5微克,范围34至88微克)和小儿储雾罐(55.5微克,范围39至76微克)治疗后。儿童的分钟通气量在1.4升/分钟至7.0升/分钟之间(平均5.0升/分钟)。这足以在30秒的吸入时间内排空所有储雾罐。结论是,对于10至25个月的儿童来说,只要使用容积低于750毫升的储雾罐,储雾罐容积似乎并非那么重要。